Literature DB >> 17406238

Design and cloning of lentiviral vectors expressing small interfering RNAs.

Gustavo Tiscornia1, Oded Singer, Inder M Verma.   

Abstract

RNA interference (RNAi) has emerged as a powerful technique to downregulate gene expression. The use of polIII promoters to express small hairpin RNAs (shRNAs), combined with the versatility and robustness of lentiviral vector-mediated gene delivery to a wide range of cell types offers the possibility of long-term downregulation of specific target genes both in vitro and in vivo. The use of silencing lentivectors allows for a rapid and convenient way of establishing cell lines (or transgenic mice) that stably express shRNAs for analysis of phenotypes produced by knockdown of a gene product. Here we present two possible protocols describing the design and cloning of silencing lentiviral vectors. These protocols can be completed in less than 3 weeks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17406238     DOI: 10.1038/nprot.2006.36

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  53 in total

1.  Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.

Authors:  Kazuo Suzuki; Takaomi Ishida; Makoto Yamagishi; Chantelle Ahlenstiel; Sanjay Swaminathan; Katharine Marks; Daniel Murray; Erin M McCartney; Michael R Beard; Marina Alexander; Damian F J Purcell; David A Cooper; Toshiki Watanabe; Anthony D Kelleher
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

2.  Mechanisms of tau and Aβ-induced excitotoxicity.

Authors:  Susanne P Pallo; John DiMaio; Alexis Cook; Bradley Nilsson; Gail V W Johnson
Journal:  Brain Res       Date:  2015-12-28       Impact factor: 3.252

Review 3.  Chemical modification: the key to clinical application of RNA interference?

Authors:  David R Corey
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  MicroRNA expression signature for Satb2-induced osteogenic differentiation in bone marrow stromal cells.

Authors:  Yiming Gong; Fei Xu; Ling Zhang; Yanyan Qian; Jake Chen; Huijun Huang; Youcheng Yu
Journal:  Mol Cell Biochem       Date:  2013-11-12       Impact factor: 3.396

5.  A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors.

Authors:  Grégory Berger; Stéphanie Durand; Caroline Goujon; Xuan-Nhi Nguyen; Stéphanie Cordeil; Jean-Luc Darlix; Andrea Cimarelli
Journal:  Nat Protoc       Date:  2011-05-19       Impact factor: 13.491

6.  Taz-tead1 links cell-cell contact to zeb1 expression, proliferation, and dedifferentiation in retinal pigment epithelial cells.

Authors:  Yongqing Liu; Ying Xin; Fei Ye; Wei Wang; Qingxian Lu; Henry J Kaplan; Douglas C Dean
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-05       Impact factor: 4.799

Review 7.  Applications of lentiviral vectors for shRNA delivery and transgenesis.

Authors:  Oded Singer; Inder M Verma
Journal:  Curr Gene Ther       Date:  2008-12       Impact factor: 4.391

8.  Zeb1 represses Mitf and regulates pigment synthesis, cell proliferation, and epithelial morphology.

Authors:  Yongqing Liu; Fei Ye; Qiutang Li; Shigeo Tamiya; Douglas S Darling; Henry J Kaplan; Douglas C Dean
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

9.  HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Elisabeth Serger; Sofia Campos; Ajit S Divakaruni; Changyoun Kim; Kendall Smith; Margarita Trejo; Anthony Adame; Brian Spencer; Edward Rockenstein; Anne N Murphy; Ronald J Ellis; Scott Letendre; Igor Grant; Eliezer Masliah
Journal:  Neurobiol Dis       Date:  2015-11-22       Impact factor: 5.996

10.  Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Authors:  Leslie Crews; Brian Spencer; Paula Desplats; Christina Patrick; Amy Paulino; Edward Rockenstein; Lawrence Hansen; Anthony Adame; Douglas Galasko; Eliezer Masliah
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.